Key result
Independent predictors of prescribing rivaroxaban over VKA for VTE included age < 65 years (OR 2.86; 95% CI 1.29-6.37), DVT versus PE (OR 2.54), and an emergency department visit (OR 2.24).
Why the study?
What are the predictors of prescribing rivaroxaban over vitamin K antagonists for the treatment of acute VTE?
Population
256 consecutive patients newly diagnosed with acute VTE admitted to an academic tertiary care center in…
Comparison
Prescription of rivaroxaban for the subsequent… vs Prescription of vitamin K antagonist (VKA)
Design
Cross-sectional
Authors
Loading...
Rivaroxaban use favored younger patients with preserved renal function and fewer comorbidities; leaves open selection biases in early DOAC adoption for VTE.
Cross-Sectional (n=256)
No
What are the predictors of prescribing rivaroxaban over vitamin K antagonists for the treatment of acute VTE?
Odds Ratio: 2.86 (95% CI 1.29–6.37)
Early after its approval, rivaroxaban was rarely prescribed for acute VTE and was preferentially used in younger patients, those with DVT, and those treated in the emergency department.
Dault et al. (2015) conducted a cross-sectional in Acute venous thromboembolism (VTE) (n=256). Rivaroxaban vs. Vitamin K antagonist (VKA) was evaluated on Prescription of rivaroxaban over VKA (predictor: age < 65 years) (OR 2.86, 95% CI 1.29-6.37). Independent predictors of prescribing rivaroxaban over VKA for VTE included age < 65 years (OR 2.86; 95% CI 1.29-6.37), DVT versus PE (OR 2.54), and an emergency department visit (OR 2.24).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: